Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
Status:
Terminated
Trial end date:
2018-11-05
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and tolerability of the addition of immunostimulatory therapy
consisting of focal radiation with or without the Toll-like receptor (TLR) agonist Poly ICLC
in patients with cutaneous T-cell lymphoma (CTCL) receiving concurrent therapy with the
histone deacetylase inhibitor (HDACI) Romidepsin.
Phase:
Phase 1
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health